Form 8-K

8-K — Valion Bio, Inc.

Accession: 0001683168-26-007300

Filed: 2026-09-23

Period: 2026-09-17

CIK: 0001787740

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — valion_8k.htm (Primary)

EX-10.1 — CONSULTING AGREEMENT (valion_ex1001.htm)

EX-99.1 — PRESS RELEASE, DATED SEPTEMBER 23, 2026. (valion_ex9901.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: valion_8k.htm · Sequence: 1

Tivic Health Systems, Inc. Form 8-K

false

0001787740

2026-09-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date

of earliest event reported): September 17,

2026

Valion

Bio, Inc.

(Exact name of Registrant as Specified in Its

Charter)

Delaware

001-41052

81-4016391

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1305 E. Houston Street,

Building 1, Suite 311

San Antonio, Texas

78205

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 888 276-6888

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

VBIO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of

Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Dean Zikria as Interim Chief

Executive Officer

On September 22, 2026, Valion Bio, Inc. (the “Company”),

a Delaware corporation, appointed Dean Zikria as Interim Chief Executive Officer of the Company, effective immediately. Mr. Zikria remains

a member of the Company’s Board of Directors (the “Board”).

Mr. Zikria, 58, has served as a director on our

Board since July 10, 2019. Mr. Zikria brings deep industry experience in allergy and asthma as well as other chronic diseases to the board.

Since August 2019, Mr. Zikria has been the Founder, CEO and Chairman of Mind Machine LLC, a Silicon Valley based marketing/advertising

agency—focused on the MedTech industry. From June 1, 2021, until January 2023, he served as the Chief Commercial Officer at Intuity

Medical Inc., a Silicon Valley MedTech company launching a highly disruptive glucose meter in the diabetes industry. In addition, he has

served as Chairman of DZ Advisors, LLC, a company founded by Mr. Zikria in 2017 that provides consulting and advisory services to the

medtech, biotech, digital health and pharmaceutical industries; since inception, where he also served as President from December 2017

until May 31, 2021. Mr. Zikria also sits on the boards of the following privately held companies: AsthmaTek, Inc., a startup digital health

company in the asthma space; Brev.Dev, Inc., a technology company developing a disruptive platform to aid developers. Mr. Zikria previously

served as Chief Executive Officer of Spirosure Inc., a FeNO detection company for asthma diagnostics, from 2014 to 2017. Additionally,

he previously served as head of global marketing for Johnson & Johnson’s Animas Corporation within their medical device &

diagnostics division. He was head of strategy for Pfizer Pharmaceuticals U.S. Cardiovascular Unit, a division with approximately $7 billion

in annual revenues. Mr. Zikria also brings experience in strategic planning, scenario planning and analysis, and mergers and acquisitions,

including sourcing, transactions and integration.

On September 22, 2026, in connection with his

appointment as Interim Chief Executive Officer of the Company, the Company and Mr. Zikria entered into a consulting agreement (the “Consulting

Agreement”), pursuant to which Mr. Zikria (i) is entitled to receive a monthly fee of $23,333 per month; (ii) is entitled to receive

50,000 restricted stock units (“RSUs”) to be issued pursuant to a nonstatutory equity grant under the Company’s Amended

and Restated 2021 Equity Incentive Plan, as amended (the “Plan”); (iii) is entitled to receive another 50,000 RSUs upon an

increase in the Company’s Plan by the Company’s stockholders, and subject to the approval of the Special Committee of the

Board and (iv) may be eligible to receive a cash bonus, as determined by the Board or the Compensation Committee of the Board, upon closing

of a strategic transaction (i.e., a reverse merger, a merger, or acquisition).

Pursuant to the Consulting Agreement, Mr. Zikria

is and will be an independent contractor. Nothing contained in the Consulting Agreement is intended or should be construed to make or

constitute Mr. Zikria as an employee or agent of the Company or a partner or co-venturer with the Company. The Consulting Agreement will

terminate on January 22, 2027, unless mutually extended by the parties up to twelve (12) months from the effective date of the Consulting

Agreement.

The foregoing summary of the Consulting Agreement

does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of

which is filed as Exhibit 10.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.

There are no family relationships between Mr.

Zikria and any of the Company’s directors, executive officers or persons nominated or chosen by the Company to become a director

or executive officer. Other than as previously disclosed, the Company is not aware of any transactions or relationships between Mr. Zikria

and the Company that would require disclosure under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended

(the “Exchange Act”).

Board Resignation

On September 17, 2026, Sheryle Bolton notified

the Company of her decision to resign from the Company’s Board, effective immediately. Ms. Bolton’s resignation was not

the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Board Committee Appointments

On September 17, 2026, the Company appointed Thomas

Jensen as Chair of the Board and Chair of the Board’s Compensation Committee, effective immediately.

On September 17, 2026, the Company appointed Jared

Malbin as Chair of the Board’s Audit and Risk Committee, effective immediately.

Mr. Zikria was removed as an independent member

from the Board’s Audit and Risk Committee, Compensation Committee and Nominations and Corporate Governance Committee while he serves

as Interim Chief Executive Officer.

Item 7.01 Regulation FD Disclosure.

On September 23, 2026, the Company issued a press

release announcing its leadership changes discussed in Item 5.02 above. A copy of the press release is being furnished as Exhibit 99.1

to this Current Report and is incorporated by reference herein.

The information set forth under Item 7.01 of this

Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of

Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities

of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into

any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in

any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission

as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1

Consulting Agreement, by and

between the Company and Dean Zikria, effective September 22, 2026.

99.1

Press Release, dated September 23, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALION BIO, INC.

Date:

September 23, 2026

By:

/s/ Melinda Lackey

Name: Melinda Lackey

Title: General Counsel and Senior Vice President of Legal Affairs

EX-10.1 — CONSULTING AGREEMENT

EX-10.1

Filename: valion_ex1001.htm · Sequence: 2

Exhibit 10.1

VALION BIO CONSULTING AGREEMENT

This CONSULTING AGREEMENT

(this “Agreement”) with an effective date of September 22, 2026 (“Effective Date”) is made by and

between Valion Bio, Inc. (the “Company” or “Valion”), and Dean Zikria (“Consultant”).

RECITALS

WHEREAS, the Company

desires to engage Consultant to perform the Services (defined below), and Consultant desires to perform such Services.

NOW, THEREFORE, in

consideration of the foregoing premises and the mutual promises herein contained, the parties agree as follows:

1. Consultant Information.

Consultant represents

and warrants for the benefit of the Company that the following information relating to Consultant is true and correct:

Consultant:

Dean Zikria

Title: Interim

Chief Executive Officer

2. Compensation.

a. Monthly Fee: Consultant shall perform agreed upon services relating to Consultant’s agreed

upon responsibilities at a rate of $23,333/month.

b. Equity: Consultant shall also be granted 50,000 restricted stock units (“RSUs”) under

the following terms:

i. The RSUs shall be issued pursuant to a nonstatutory equity grant under the Company’s Equity Incentive

Plan;

ii. Another 50,000 RSUs upon an increase in the Company’s equity incentive plan by the Company’s

stockholders, and subject to the Special Committee of the Board of Directors of the Company’s (the “Special Committee”)

approval;

iii. One fourth of any issued RSUs shall vest quarterly on the three-month anniversary of the Effective Date

over twelve months; and

iv. Should the Company undergo a change of control (as defined in the Company’s Equity Incentive Plan),

all issued RSUs as of that date shall vest immediately.

c. Bonus: Consultant shall also be entitled to a cash bonus upon closing of a strategic transaction

(i.e., a reverse merger, a merger, or acquisition), the amount of which shall be determined at the time of said transaction, based on

the nature of the transaction.

d. Expenses: Reasonable pre-approved out of pocket expenses shall be reimbursed within seven (7) days

of submission. The Chair of the Board will approve all expenses.

3. Payment Terms.

Service Provider does not need to

submit invoices for payment. Payment will be rendered automatically on the Effective Date and then on the monthly anniversary of the

Effective Date, via wire transfer to account identified by Consultant.

4. Work Responsibilities.

Consultant shall be

responsible for at least those activities provided at Exhibit A, including others that may be assigned by the Special Committee of the

Board of Directors of Valion Bio, Inc. (the “Committee”), and by Thomas Jensen, as chair of the Committee. Consultant will

also work closely with the current management team to direct and lead the Company.

Consultant will be

issued a Company laptop and a Company Microsoft 365 licensed account, including a Valion Bio email address. All services rendered under

this Agreement must be conducted using the Company laptop and license, including the email address and our backed up storage capabilities,

not on personal computers or personal email. The laptop must be returned upon termination of this Agreement, without being wiped or reformatted

to allow appropriate archival of Company intellectual property.

Consultant acknowledges

that this Agreement results in his director position with the Company being non-independent. Consultant agrees that his position as a

member of the Committee, as well as the Compensation, Audit and Risk, and Nominations and Corporate Governance Committees must be terminated

during the term of this Agreement. Consultant will continue to be a director. Upon termination of this Agreement and re-establishment

of Consultant’s independence, reappointment to committees shall be subject to the Nominations and Corporate Governance Committee’s

assessment and appointment and Committee or Board approval of the same.

Consultant shall not

have independent signatory authority on behalf of the Company, except with respect to any regulatory or statutory filings or representations.

Any contracts over $100,000 in total require pre-approval by the Finance Subcommittee of the Board of Directors of the Company before

signature by the Consultant. Any contracts over $250,000 in total require pre-approval by the Special Committee before signature by the

Consultant.

5. Relationship of the Parties.

a. For all purposes of this Agreement and the performance of work hereunder, Consultant is and will be an

independent contractor. Nothing contained in this Agreement is intended or should be construed to make or constitute Consultant as an

employee or agent of the Company or a partner or co-venturer with the Company.

b. Without limiting the generality of the foregoing, Consultant acknowledges and agrees that (i) the Company

will not be withholding any federal, state, local or social security taxes from any payments due to Consultant, (ii) Consultant is solely

responsible for the payment of all such taxes, and (iii) Consultant will not be covered by or otherwise eligible for any benefits, including,

without limitation, employment insurance and worker’s compensation insurance, that the Company provides to its employees.

6. Term of Agreement.

a. This Agreement shall expire on January 22, 2027, after which the Parties may mutually agree to extend

to up to twelve (12) months from the Effective Date.

b. The intent of the Parties is for Consultant to return to the Company’s Board of Directors as an

independent director, with that assessment being made at that time by the relevant committees of the Board of Directors.

7. Representations of Consultant.

Consultant further

represents and warrants for the benefit of the Company that:

a. Consultant has full legal authority to enter into this Agreement and provide the Services hereunder, and

this Agreement constitutes the legal, valid and binding obligation of Consultant enforceable against Consultant in accordance with its

terms. Neither any of the terms of this Agreement nor the performance by Consultant of work hereunder does or will violate the terms of

any agreement between Consultant and any third party.

b. Consultant will perform all work hereunder in a professional manner and in accordance with the highest

standards of skill and care in Consultant’s business and profession. Consultant shall adhere strictly to all of the Company’s

standards and policies as they shall be communicated to Consultant from time to time, as well as all applicable federal, state and local

laws, rules and regulations. Consultant shall maintain and make available to the Company accurate and reasonably detailed records of Consultant’s

time dedicated to the performance of the Services hereunder and any fees or expenses incurred by Consultant in connection with the performance

of the Services.

c. To the best of Consultant’s knowledge, no material furnished by Consultant to the Company under

this Agreement will infringe any copyright or other intellectual property right of any person, will be libelous, will otherwise violate

the rights of or cause damage to any person or entity, or will violate any law, rule or regulation.

d. As a condition of your engagement with the Company, Consultant certifies and affirms that Consultant

is not under investigation by the FDA for debarment action, has not been debarred under the Generic Drug Enforcement Act of 1992 (21 U.S.C.

301 et seq.), and is not otherwise being investigated, restricted or disqualified from performing services relating to clinical trials

by the FDA or any other regulatory authority or professional body in any other jurisdiction. If, during the course of Consultant’s

engagement with the Company, Consultant becomes subject to such investigation or otherwise are restricted or disqualified, Consultant

will promptly inform Valion’s Legal Department of such event.

8. Ownership of Materials.

a. All documents, data, diagrams, formulations, formulas, indications, records, customer lists, any physical

embodiment of or documentation relating to Discoveries, equipment and other items provided by the Company and held in the possession of

Consultant, and any other materials, in any form (collectively, ”Materials”), which in any way relate to the Company’s

past, present or potential business and which were prepared or received by Consultant after the Effective Date and in the course of Consultant’s

performance of the Services are the exclusive property of the Company. Consultant specifically acknowledges that Consultant has no ownership

interests or rights of any kind in or to such materials even if Consultant developed such materials. Consultant further agrees to deliver

to the Company at the request of the Company all copies of such materials, including Consultant’s own personal work papers, and

in the absence of such request, upon the termination of Consultant’s services hereunder pursuant to Section 16 below. Consultant

warrants that Consultant has not and will not at any time hereafter make, create or retain copies of any such materials except that Consultant

may retain one copy of such materials solely for archival purposes.

b. This Agreement does not grant any rights to or modify the ownership of any Materials of either Party existing

prior to the Effective Date, or any Materials of Consultant that are created after the Effective Date and not in the course of Consultant’s

performance of the Services.

9. Trade Secrets.

a. Consultant acknowledges that the Company’s formulas, formulations, indications, its research and

development activities, its sources of supply, its techniques, Discoveries to the extent not disclosed to the public by the Company (collectively

“Trade Secrets”), as well as further developments, improvements, or refinements thereto, are uniquely valuable to the

Company, have been developed through considerable expense and effort, and are not disclosed to the public.

b. In light of the need to preserve the confidentiality of these Trade Secrets, and in consideration for

Consultant’s compensation hereunder, Consultant agrees, at all times while providing the Services to the Company and at all times

thereafter, regardless of the reason Consultant ceases to perform the Services for the Company, to protect the confidentiality of the

Trade Secrets, to use them solely for the benefit of the Company’s business, and to refrain from using or disclosing or making available

the Trade Secrets to any third party without the express prior written consent of an authorized officer of the Company. Consultant further

agrees to take all reasonable security measures requested by the Company to prevent accidental disclosure.

10. Confidential Information.

Except as may be required or appropriate

in connection with carrying out assigned duties under this Agreement, Consultant shall not, without the express prior written consent

of an authorized officer of the Company, or as may otherwise be required by law or legal process, communicate to anyone other than the

Company and those designated by the Company in the furtherance of its business, any Confidential Information (as hereafter defined) obtained

by Consultant during the performance of the Services for the Company. Consultant acknowledges that some Confidential Information may not

qualify as a Trade Secret but is still uniquely valuable and an important asset of the Company, and as such Consultant agrees to hold

the Confidential Information in trust for the Company’s sole benefit. Therefore, at all times while performing the Services hereunder

and at all times thereafter, Consultant shall not use any of the Confidential Information for Consultant’s own personal benefit

or for the benefit of third parties without the express prior written consent of an authorized officer of the Company, unless required

by law or legal process. “Confidential Information,” as used in this Agreement, will include all information, or compilation

or analysis of information, that is not generally available to the public (other than by acts of Consultant in violation of this Agreement)

that involve the business affairs or operations of the Company including, but not limited to, the following: this Agreement and all provisions

hereof; all information acquired by Consultant from the Company, its vendors, suppliers, advertisers, customers or others during Consultant’s

performance hereunder that relates to the Company’s past, present or potential business or operations; all information regarding

the Company’s programs, files, employment contracts, personnel information and financial information; all information constituting

Discoveries (as defined in Section 11 hereof) or Trade Secrets; all information regarding the Company’s computer systems,

software, source code, source listing, program listing, flowcharts, schematics, design documents, technical information or material or

other information relating to computer programs (including, without limitation, related documentation and/or hardware developed or modified

by or on behalf of the Company, and any modifications and enhancements thereto developed by or on behalf of the Company); all information

regarding the Company’s past, present or future research and development plans or strategies, business plans or strategies, business

activities or affairs, licensing arrangements, marketing or sales plans, product development plans, distribution plans or activities,

production plans or methods and/or manufacturing plans or methods; as well as documents or records containing price lists, catalogs, quotes,

leads, customer lists, vendor or supplier lists, vendor or supplier contract terms and conditions, licensing terms and conditions, customer

contracts, customer requirements or specifications, and contract supply information.

Consultant acknowledges that, during

the course of Consultant’s performance under this Agreement, Consultant has or will receive material nonpublic information that,

if known to the public, would affect the Company’s stock price. Consultant shall not purchase or sell the Company’s stock

or any equity instrument related to the Company’s stock “on the basis of,” as such term is defined in Rule 10b5-1 of

the Securities and Exchange Act of 1934, any material nonpublic information disclosed in discussions and exchanges between the Company

and Consultant until such material nonpublic information is disclosed to the public.

11. Discoveries.

a. All Discoveries are the exclusive property of the Company, and Consultant will promptly and fully disclose

them to the Company. As used herein, the term “Discoveries” means all discoveries, inventions, improvements,

formulas, formulations, indications, and processes, in any form, whether or not patentable or copyrightable (including records thereof),

as well as all Intellectual Property (as defined herein), which Consultant alone or with others under the Company’s direction or

in connection with the Company’s business may invent, discover, make or conceive, after the Effective Date, and whether the Company’s

facilities are used or not. As used herein, the term “Intellectual Property” means all current and future worldwide

patents and other patent rights, inventions, formulas, formulations, indications, copyrights, trade secrets, trademarks, know-how, utility

models and other intangible proprietary rights, including, without limitation, all applications and registrations with respect thereto.

Consultant agrees that all copyrightable or patentable Discoveries are “works made for hire” and shall be the sole and complete

property of the Company. Immediately, at the Company’s expense, Consultant will, without further compensation: (i) promptly record

such Discoveries; (ii) execute any assignments and other documents that the Company deems desirable to protect its rights in the Discoveries;

and (iii) assist the Company in enforcing its rights with respect to these Discoveries. To the extent that such Discoveries are not deemed

to be “works made for hire”, Consultant hereby assigns all proprietary rights, including copyrights, in these works to the

Company without further compensation. Consultant’s obligations hereunder will survive termination of this Agreement.

b. This Agreement does not grant any rights to or modify the ownership of any Intellectual Property of either

Party existing prior to the Effective Date, or any Intellectual Property of Consultant that is created after the Effective Date and not

in the course of Consultant’s performance of the Services.

12. Restrictions on Unfair Competition.

It is recognized by

Consultant that, as a natural result of performing the Services, Consultant may be involved in the creation and development of Discoveries,

including Intellectual Property, and/or Trade Secrets and will gain access to the Discoveries, Trade Secrets and Confidential Information.

Further, Consultant will gain the trust, confidence and respect of the Company’s employees, customers, suppliers and other parties

with whom the Company has business, contractual relationships, or both. Consultant acknowledges that the Company has a legitimate need,

in addition to all other protections pertaining to Discoveries, Trade Secrets and Confidential Information provided to the Company in

this Agreement, to protect itself against unfair competition by its existing and former Consultants. Therefore, in consideration of the

compensation to be paid to Consultant hereunder, Consultant agrees that while performing the Services hereunder and for six (6) months

after the termination of this Agreement, Consultant will not:

a. provide a Competitive Service (as defined below) to a business that is competing, attempting to compete,

or intending to compete with the Company; or

b. disrupt the Company’s operations and its relationships with its employees by (i) inducing or encouraging

or attempting to induce or encourage any employee of the Company to terminate his or her employment or to work for a competitive business,

(ii) hiring, attempting to hire, or assisting another to hire or attempt to hire any employee of the Company to work for a competitive

business, or (iii) inducing or encouraging or attempting to induce or encourage a Consultant or supplier of the Company or any other party

with which the Company has a business relationship to terminate, fail to renew, or substantially change its business relationship with

the Company. For clarify, Consultant may engage service providers engaged by the Company, but only for matters unrelated to Company’s

operations, with prior written consent, which will not be unreasonably withheld.

The term “Competitive

Service” shall mean services that are the same or substantially similar to the services provided by Consultant on behalf of

the Company during the term of Consultant’s performance of the Services for the Company hereunder and shall also mean assisting,

supervising, or directing others to perform these same Services on behalf of a competitive company. The restrictions in this Section are

not intended to, and will not be constructed to, prevent Consultant from seeking or obtaining work in the same field as the Company in

the United States or elsewhere so long as the work performed does not involve Consultant providing a Competitive Service on a Competing

Product. The term “Competing Product” shall mean a component or similar product and/or product candidate, that (i)

the Company has under design or development, has under license or is manufactured or sold by, or on behalf of, the Company at any time

within the term of Consultant’s performance of the Services for the Company hereunder, and (ii) about which Consultant acquired

non-public information during the performance of services for the Company hereunder. Competitive Service shall not include Consultant’s

continued employment with Mind Machine Co or conducting his regular business with that company.

13. Reasonableness of Restrictions.

Consultant has read

and considered carefully the restrictions on unfair competition contained in this Agreement and acknowledges that the restrictions are

fair and reasonably required for the protection of the interests of the Company, its business and its officers, directors, members and

employees. Consultant agrees that these restrictions are reasonable in the context of this Agreement as the type of work to be performed

by Consultant on behalf of the Company.

14. Severability.

a. The parties recognize that this Agreement contains various provisions and imposes several separate

restrictions on Consultant during and after Consultant’s performance of the Services hereunder. Each Section of this Agreement,

each provision contained in separate subsections of the Section, and each separate restriction within each subsection are intended to

stand alone and are not dependent on any other covenant or provision, unless expressly so stated therein. Therefore, should a court rule

that any provision or provisions of this Agreement are unenforceable or invalid for any reason, and if the offending provision(s) cannot

be reformed in order to make them enforceable, then the offending provision shall be severed from the Agreement, and the remaining provisions

shall be unaffected and fully enforced as if the offending provision was never contained in the Agreement.

b. In the event that a court determines that a provision or provisions of this Agreement are overbroad, or

are unenforceable or invalid for any other reason, the parties authorize the court to modify the offending provision(s), and the court

shall modify the offending provisions in order to make it enforceable in the most restrictive fashion permitted by law. In so doing, Consultant

authorizes the court to impose the revised restriction retroactively.

c. No breach, or alleged breach by the Company of any of the provisions of this Agreement, or of any other

duty or obligation which may be owed to Consultant, shall be asserted by Consultant or shall serve as a bar or defense to any action by

the Company to enforce any of its provisions.

15.

Enforcement.

Consultant understands

and agrees that the Company will suffer irreparable harm if Consultant breaches any of Consultant’s obligations under Sections

7, 8, 9, 10, 11 12, 19 and 21 of this Agreement, and that monetary damages will be inadequate to compensate the Company for any such

violations. Accordingly, Consultant agrees that in the event Consultant violates or threatens to violate any of the referenced provisions

of this Agreement, the Company, in addition to all of the remedies which it may have at law, will be entitled to temporary, preliminary,

and permanent injunctions to prevent or to restrain any such actual or threatened violation by Consultant, or by any or all of the contractors,

partners, employers, agents or other persons, directly or indirectly acting for, or on behalf of, or with Consultant, as well as damages

and an equitable accounting of earnings, profits and other rights or remedies to which the Company may be entitled. Consultant consents

to the issuance of such injunctions or the imposition of such damages and accountings as being a reasonable measure to protect the Company’s

rights.

16. Termination.

a. Either party may terminate this Agreement upon thirty (30) days written notice to the other party.

b. This Agreement will automatically terminate (i) in the event of Consultant’s death or incapacity,

and/or (ii) upon any other circumstance under which Consultant is unable to perform Consultant’s obligations pursuant to this Agreement.

c. Fees shall continue to accrue during the notice period. Any termination of the Agreement not for

Cause (defined as means the occurrence of any of the following: (A)

conviction for, or plea of no contest to, a felony or a crime involving moral turpitude; (B) commission of an act of personal dishonesty

that is intended to result in Consultant’s personal enrichment (excluding inadvertent acts that are promptly cured following notice);

(C) a continued material failure or failures by Consultant to perform Consultant’s lawful and reasonable duties of employment (including,

but not limited to, compliance with material written policies of the Company and material written agreements with the Company) (but only

after the Company has delivered a written demand for performance to Consultant that describes the basis for the Company’s belief

that Consultant has committed material violations and Consultant has not cured within a period of 15 days following notice); (D) willful

failure (other than due to physical incapacity) to reasonably cooperate with any audit or investigation by a governmental authority or

the Company of the Company’s business or financial conditions or practices that continues after written notice from the Board and

at least fifteen (15) days to cure; (E) it is determined that Consultant has conducted his self in an unprofessional, unethical, illegal

or fraudulent manner, or have acted in a manner detrimental to the reputation, character or standing of the Company, or to the financial

condition of the Company, including, but not limited to theft or misappropriation of Company’s assets, engaging in unlawful discriminatory

or harassing conduct, working while under the influence of alcohol or illegal drugs, or the filing of false expense or related reports;

(G) a material breach of any of Consultant’s fiduciary duties to the Company; (H) any willful, material violation by Consultant

of any law or regulation applicable to the business of the Company; (I) a material breach of any of the covenants, representations and

warranties contained herein; or (J) insubordinate conduct so divergent from the Company’s purpose, that a majority vote by the Board

necessitates Consultant’s removal) shall result in an immediate vesting, as of the last day of service, of thirty-three percent

(33%) of any issued RSUs as of the last day of service.

17. Litigation Issues.

a. Choice of Law. The parties agree that this Agreement is to be governed by and construed under the

laws of the State of Delaware applicable to agreements made and to be fully performed therein, excluding conflicts of law provisions thereof.

b. Dispute Resolution and Jurisdiction. If a dispute arises between the parties concerning any right

or duty under this Agreement, then the parties will confer, as soon as practicable, in an attempt to resolve the dispute through mediation.

If the parties are unable to resolve the dispute amicably through mediation, then the parties agree to resolve the matter via arbitration,

the terms of which shall be agreed to at a later date, if needed.

18. Prior Commitments.

Consultant acknowledges

and represents that Consultant is not a party to any other agreements, relationships or commitments to any other person or entity that

conflict with Consultant’s obligations to the Company under this Agreement. Consultant will not disclose to the Company, use or

induce the Company to use any confidential or proprietary information or trade secrets of others.

19. Indemnification by Consultant.

Consultant shall defend,

indemnify, and hold harmless the Company and the Company’s officers, directors, shareholders, agents and employees from and against

any and all third party losses, liabilities, damages, demands, suits, causes of action, judgments, costs or expenses (including court

costs and reasonable attorney fees) resulting from or directly or indirectly arising out of or in connection with this Agreement and the

transactions contemplated hereby, including but not limited to: (1) any claim that any negligent acts or omissions of Consultant caused

personal injury, death, property damage, or any other legal or equitable wrong; (2) any obligation or tax liability imposed on the Company

resulting from Consultant’s being determined not to be an independent contractor; and (3) a breach of any covenant, representation

or warranty made herein by Consultant. The Company shall have the right to approve any counsel retained to defend any demand, suit, or

cause of action in which the Company is a defendant, such approval not to be unreasonably withheld. Consultant agrees that the Company

shall have the right to control and participate in the defense of any such demand, suit or cause of action concerning matters that relate

to the Company, and that such suit will not be settled without the Company’s consent, such consent not to be unreasonably withheld.

If, in the Company’s judgment, a conflict exists in the interests of the Company and Consultant in such demand, suit, or cause of

action, the Company may retain its own counsel whose fees shall be paid by Consultant.

Nothing herein shall

be construed as making Consultant liable for any injury or damage caused solely by the negligence or wrongdoing of the Company.

Consultant shall continue

to be a party to that certain Indemnity Agreement between Consultant and the Company as part of Consultant’s service as a director.

20. Notices.

All notices, demands or other communications

given hereunder shall be deemed to have been duly given only upon hand delivery thereof or upon the first business day after delivery

to a reputable international overnight courier service for overnight delivery, addressed as set forth below, or to such other address

or such other person as either party shall designate in writing to the other for such purposes and in the manner set forth herein. Notices

to Consultant are to be addressed to the address as provided by the Consultant in the signature block. Notices to the Company are to be

addressed as follows:

If to the Company:

Valion Bio, Inc.

1305 E. Houston Ave

Suite 311, Building 1

San Antonio TX 78205

Attention: Legal

Email Address: legal@valionbio.com

with a copy to (which shall not constitute

notice):

Snell & Wilmer L.L.P.

3611 Valley Centre Drive, Suite 500

San Diego, CA 92130

Attention: Christopher Tinen

Email: ctinen@swlaw.com

21. Miscellaneous.

a. The recitals to this Agreement are incorporated herein by reference and made a part hereof.

b. No delay or failure by the Company to exercise any right under this Agreement, and no partial or single

exercise of that right, will constitute a waiver of that or any other right provided herein, and no waiver of any violation of any term

or provision of this Agreement will be construed as a waiver of any succeeding violation of the same or any other provision of the Agreement.

c. The parties hereto expressly agree that this Agreement was jointly drafted, and that they both had opportunity

to negotiate its terms and to obtain the assistance of counsel in reviewing its terms prior to execution. Therefore, this Agreement shall

be construed neither against nor in favor of either party, but shall be construed in a neutral manner.

d. This Agreement may not be assigned by the Company and by any of its successors or assigns without Consultant’s

consent, which will not be unreasonably withheld. This Agreement may not be assigned by Consultant.

e. The provisions of this Agreement set forth in Sections 5 through 19 will survive the termination

of this Agreement.

f. This Agreement and the Exhibit hereto constitute the complete understanding of the parties with respect

to the subject matter set forth herein, and shall supersede any prior understanding or agreement to the contrary, written or oral, as

it relates to the appointment of Consultant by the Company and may not be amended, modified or altered unless in a writing signed by all

parties hereto.

To memorialize their understanding and agreement

to the terms and conditions set forth above, the parties hereby sign this Agreement.

VALION

BIO, Inc.

By:

/s/ Lisa Wolf

Date: September 22, 2026

Lisa Wolf

Chief Operating Officer

CONSULTANT

Dean Zikria

By:

/s/ Dean Zikria

Date: September 22, 2026

Email:

Address:

Exhibit A — Scope of the engagement

1. Capital

Financing strategy and execution

2. Entolimod

and regulatory pathway(s) of the same

3. Public

company compliance and governance

4. Business

development and strategic transactions

5. General

corporate and operations for both Valion Bio & Velocity Bioworks

EX-99.1 — PRESS RELEASE, DATED SEPTEMBER 23, 2026.

EX-99.1

Filename: valion_ex9901.htm · Sequence: 3

Exhibit 99.1

Valion Appoints Life Sciences Veteran

Dean Zikria as Interim CEO and Announces Board Leadership Transitions

Leadership changes strengthen alignment and

execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities

SAN ANTONIO, TX – September 23, 2026

– Valion Bio, Inc. (Nasdaq: VBIO) (“Valion” or the “Company”), a clinical-stage biopharmaceutical

company, today announced decisive changes to its executive leadership team and Board of Directors (the “Board”). These leadership

transitions are intended to strengthen organizational alignment and support focused execution as Valion advances its Entolimod and other

development programs and evaluates strategic opportunities.

Dean Zikria, a current member of the Board, has

been appointed Interim Chief Executive Officer (“CEO”). In this role, Mr. Zikria will oversee Valion’s strategic priorities,

including accelerating the clinical advancement of Entolimod and aggressively pursuing commercial and government partnerships.

Mr. Zikria brings a compelling blend of scientific

innovation, pharmaceutical commercialization and emerging biotech experience to Valion’s next phase of growth. His career began

at Columbia University Medical Center, where he co-invented novel therapeutics studied for potential applications in traumatic brain injury,

hemorrhagic shock and battlefield medicine, and later included seven years at Pfizer, where he held strategy and business development

roles within its $7 billion U.S. cardiovascular business, supporting a portfolio that included LIPITOR®, then the world’s best-selling

drug. Today, he remains at the forefront of emerging biotechnology as an advisor and selection committee member for UC Berkeley’s

SkyDeck accelerator, evaluating new therapeutic technologies and advising early-stage companies on R&D strategy, financing, leadership

and commercialization.

Lisa Wolf will continue to serve as Valion’s

President, Chief Operating Officer and Chief Financial Officer, leading the Company’s financial and operational functions and reporting

to Mr. Zikria.

Valion also announced that Thomas Jensen has been

appointed Chair of the Board and Chair of its Compensation Committee. He succeeds Sheryle Bolton, who has stepped down from the Board

and its committees. In addition, Jared Malbin has been appointed Chair of the Board’s Audit Committee.

“On behalf of the Board, I want to thank

Sheryle for her leadership, service and many contributions to Valion,” said Mr. Jensen. “These transitions establish clear

accountability and strengthen alignment between our Board and management team as Valion enters an important stage of its development.

Dean’s familiarity with the Company, its programs and its strategic priorities provides continuity while sharpening our focus on

disciplined capital allocation, operational execution and long-term shareholder value.”

“Dean brings the experience, judgment and

strategic perspective needed to lead Valion during this next phase,” Mr. Jensen continued. “The Board looks forward to working

closely with him and the broader management team as the Company advances Entolimod, evaluates high-potential opportunities and works toward

milestones that could create meaningful value for patients and shareholders.”

“I am honored to assume this expanded role

at an important point in Valion’s evolution,” said Mr. Zikria. “Valion has promising development programs and a dedicated

team working to translate the Company’s science into meaningful outcomes. My immediate priorities are to work closely with Lisa

and the rest of our team to maintain momentum, sharpen execution and concentrate our resources on Entolimod and the opportunities we believe

offer the greatest potential to create lasting value.”

About Valion Bio, Inc.

Valion Bio, Inc. (Nasdaq: VBIO) is developing

biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease

and immune dysregulation.

The Company’s lead candidate, Entolimod,

is being developed as a potential medical countermeasure for Acute Radiation Syndrome and has been evaluated in animal models under the

U.S. Food and Drug Administration’s (“FDA”) Animal Rule, which allows the Agency to approve new drugs and biological

products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of acute radiation

exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated with cellular

protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations from the FDA.

Valion is also advancing Entolasta, a next-generation

TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company’s pipeline

includes potential programs in neutropenia and immune dysfunction.

Valion’s wholly owned subsidiary, Velocity

Bioworks, is a biologics contract development and manufacturing organization providing development and manufacturing services to Valion

to support its internal pipeline, with the objective of increasing manufacturing control, reducing costs, accelerating development timelines

and strengthening domestic supply-chain security.

For more information, visit www.valionbio.com.

Forward-Looking Statements

This press release may contain "forward-looking

statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained

in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by

the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,”

“expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,”

“predict,” “project,” “target,” “aim,” “should,” “will” “would,”

or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking

statements are based on Valion’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are

difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be

accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors,

including, without limitation: the continued listing of the Company’s common stock on the Nasdaq Capital Market; and the Company's

ability to maintain compliance with applicable listing standards on the Nasdaq Capital Market. Given these risks and uncertainties, you

are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other

important factors, any of which could cause Valion’s actual results to differ from those contained in the forward-looking statements,

see Valion’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the

SEC on March 30, 2026, under the heading "Risk Factors"; as well as the Company’s subsequent filings with the SEC. Forward-looking

statements contained in this press release are made as of this date, and Valion undertakes no duty to update such information except as

required by applicable law.

Investor and Media Contact

Stephen Kilmer

(646) 274-3580

stephen.kilmer@valionbio.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Sep. 17, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 17, 2026

Entity File Number

001-41052

Entity Registrant Name

Valion

Bio, Inc.

Entity Central Index Key

0001787740

Entity Tax Identification Number

81-4016391

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1305 E. Houston Street,

Entity Address, City or Town

San Antonio

Entity Address, State or Province

Entity Address, Postal Zip Code

78205

City Area Code

888

Local Phone Number

276-6888

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

VBIO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration